


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Kaisa Health Group Holdings Limited
佳兆業健康集團控股有限公司
(Incorporated in Bermuda with limited liability)
(Stock Code: 876)

POLL RESULTS OF THE SPECIAL GENERAL MEETING
HELD ON 23 JULY 2021

Reference is made to the circular of Kaisa Health Group Holdings Limited (the “**Company**”) dated 23 July 2021 (the “**Circular**”). Capitalised terms used herein shall have the same meanings as defined in the Circular unless the context requires otherwise.

POLL RESULTS

The Board is pleased to announce that on Friday, 23 July 2021, the proposed ordinary resolution (the “**Ordinary Resolution**”) as set out in the notice of the SGM dated 8 July 2021 was duly passed by the Independent Shareholders at the SGM by way of poll. The poll result in respect of the Ordinary Resolution is as follows:

Ordinary Resolution	Number of votes (approximate%)		Total number of votes cast
	For	Against	
<p>“THAT:</p> <p>(a) the agreement dated 24 May 2021 entered into by and among Zhejiang Jinyun Medical Technology Consulting Co., Ltd.* (浙江金韻醫學科技諮詢有限公司), Kaisa Investment (Ningbo) Co., Ltd.* (佳兆業投資(寧波)有限公司), Shulan Medical Management Group Co., Ltd.* (樹蘭醫療管理集團有限公司), Shanghai Shulan Investment Co., Ltd. (上海樹蘭投資有限公司), Hangzhou Jiayue Investment Partnership* (杭州佳躍投資合夥企業(有限合夥)), Hangzhou Jinyun Investment Management Co., Ltd.* (杭州金韻投資管理有限公司), Hangzhou Shulan Hospital Co., Ltd.* (杭州良運樹蘭醫院有限公司), Kaisa Group (Shenzhen) Co., Ltd. (佳兆業集團(深圳)有限公司) and Zhejiang Jinyun Medical Technology Consulting Co., Ltd.* (浙江金韻醫學科技諮詢有限公司), and the Disposal (as defined and described in the circular of the Company dated 8 July 2021) at contemplated thereunder, and all other transactions in connection therewith and any other ancillary documents; and</p> <p>(b) any one of the directors of the Company or the company secretary of the Company be and are hereby authorised for and on behalf of the Company to sign, seal, execute, perfect, perform, deliver all such agreements, instruments, documents and deeds, and do all such acts, matters and things and take all such steps as they may in their discretion consider necessary, desirable or expedient to implement and/or to give effect to the Disposal and all other transactions thereby contemplated as they may in their discretion consider to be desirable and in the interests of the Company.</p>	<p>522,051,720 100%</p>	<p>0 0%</p>	<p>522,051,720 100%</p>

* For identification purpose only

As more than 50% of the votes were cast in favour of the Ordinary Resolution, the Ordinary Resolution proposed at the SGM was duly passed as an ordinary resolution of the Company.

As at the date of the SGM, the Company has 5,042,139,374 Shares in issue. As at the date of the SGM, Kaisa Group and its associates hold together, directly or indirectly, 2,167,600,491 Shares, representing approximately 42.99% of the entire issued share capital of the Company. In accordance with the requirements of the Listing Rules, Kaisa Group and its associates abstained from voting on the Ordinary Resolution at the SGM in respect of the Sale and Purchase Agreement and the Disposal.

Accordingly, the total number of Shares entitling the Independent Shareholders to attend and vote for or against the Ordinary Resolution in respect of the Sale and Purchase Agreement and the Disposal at the SGM was 2,564,218,883 Shares.

Save as disclosed, (i) none of the Shareholders were required to abstain from voting at the SGM; (ii) no Shareholders had stated any intention in the Circular to vote against the ordinary resolution at the SGM; and (iii) there were no Shares entitling the Shareholders to attend and abstain from voting in favour of the Ordinary Resolution at the SGM.

The Company's branch share registrar, Tricor Tengis Limited, was appointed as the scrutineer at the SGM for the purpose of vote-taking.

By order of the Board
Kaisa Health Group Holdings Limited
Zhung Huagang
Chairman

Hong Kong, 23 July 2021

As the date of this announcement, the Board comprises five executive Directors, namely Mr. Zhang Huagang (Chairman), Mr. Luo Jun (Chief Executive Officer and Co-Vice Chairman), Mr. Wu Tianyu (Co-Vice Chairman), Mr. Kwok Ying Shing and Ms. Kwok Ho Lai, and three independent non-executive Directors, namely Dr. Liu Yanwen, Dr. Lyu Aiping and Ms. Li Yonglan.